Publications by authors named "Keichi Sakamoto"
Article Synopsis
- Maintenance avelumab is recommended for patients with metastatic urothelial carcinoma (mUC) who have stable disease after first-line chemotherapy, while pembrolizumab offers an alternative option.
- In a study of 626 patients, those transitioning from first-line chemotherapy to pembrolizumab had better outcomes in terms of response and progression-free survival compared to those moving to avelumab, especially if they had a partial response.
- Overall survival rates were similar for both treatment options, highlighting that while pembrolizumab may provide better short-term efficacy, long-term survival outcomes remained unchanged.
Article Synopsis
- The study aimed to gather real-world evidence on the effectiveness and safety of enfortumab vedotin for treating unresectable or metastatic urothelial carcinoma in Japan, as data on this drug was limited.
- Researchers analyzed data from 556 patients diagnosed with metastatic urothelial carcinoma between 2008 and 2023, including 34 patients who received enfortumab vedotin, assessing treatment responses and survival outcomes.
- The results showed that 56% of patients had a partial response to the drug, with a median overall survival of 16 months and 76% experiencing some level of treatment-related toxicity, primarily skin issues.
First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer.
Nobutaka Nishimura Makito Miyake Takuto Shimizu Toshihiko Matsubara Tatsuki Miyamoto Keichi Sakamoto
Int J Clin Oncol
November 2022
Background: First-line pembrolizumab is available for recurrent disease within 12 months after the receipt of platinum-based perioperative chemotherapy. However, the benefit of first-line pembrolizumab is unclear. This study evaluated the oncological outcome of patients treated with pembrolizumab compared with chemotherapy as first-line therapy for early relapsing disease after the receipt of platinum-based perioperative chemotherapy.
View Article and Find Full Text PDF